

26 November 2025

RESULTS OF ANNUAL GENERAL MEETING

Bioxyne Limited (ASX:BXN) is pleased to advise that at the Annual General Meeting held on 26 November 2025, all resolutions were passed on a poll.

In accordance with Section 251AA(2) of the Corporations Act 2001 and Listing Rule 3.13.2 the details of the proxy votes lodged and poll are as attached.

▶ Approved by the Board of Bioxyne Limited for release to the ASX.

Guy Robertson

Company Secretary







Bioxyne Limited

Appendix

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2


Instructions given to validly appointed proxies

10	The following information is provided in	n accordance with
	Resolution details	
Ė		
(Resolution	Resolution Type
	1 Renumeration Report	Ordinary
(
	2 Re-election of Director – Mr Anthony	Ordinary
-		
	3 Approval of Issue of Performance Rights to Samuel Watson	Ordinary
	_	
	4 Approval of Issue of Performance Rights to Jason Hine	Ordinary
(5 Ratification of Placement Shares - Listing Rule 7.1A	Ordinary
(
(6 Ratification of Placement Options - Listing Rule 7.1	Ordinary
	9	
9	Approval to issue shares and options to Anthony Ho to enable his subscription in the March Placement	Ordinary
-(D	
9	8 Approval to issue shares and options to Jason Hine to enable his subscription in the March Placement	Ordinary
9		
1	9 Ratification of Broker Options	Ordinary
(
	10 Approval of Additional 10% Placement Capacity	Special

	o ramany appoint	ou proxico			1-
(as at proxy close)					(
For	Against	Proxy'sDiscretion	Exclusions	Abstain	
502,943,845	140,452,294	0	0	665,941,727	
78.17%	21.83%	0.00%			
1,168,761,842	7,911,124	0	0	132,664,900	
99.33%	0.67%	0.00%			
528,178,795	142,625,277	0	0	638,533,794	
78.74%	21.26%	0.00%			
528,178,795	142,625,277	0	0	638,533,794	
78.74%	21.26%	0.00%			
1,173,802,179	202,470	0	0	135,333,217	
99.98%	0.02%	0.00%			
1,173,802,179	202,470	0	0	135,333,217	
99.98%	0.02%	0.00%			
1,149,238,712	180,687	0	0	159,918,467	
99.98%	0.02%	0.00%			
1,174,860,247	180,687	0	0	134,296,932	
99.98%	0.02%	0.00%			
1,176,478,369	232,970	0	0	132,626,527	L
99.98%	0.02%	0.00%			Ĺ
1,160,567,388	148,604,544	0	0	165,934	
88.64%	11.35%	0.00%			L
 Share and and accorded	a and a data a star as	acuired majority on a nell			

Number of votes cas	st on the poll			Resolution
(where applicable)				Result
For	Against	Exclusions	Abstain*	Carried / Not Carried
502,943,845	140,452,294	0	665,941,727	Carried
38.41%	10.73%			
1,168,761,842	7,911,124	0	132,664,900	Carried
89.26%	0.60%			
528,178,795	142,625,277	0	638,533,794	Carried
40.34%	10.89%			
528,178,795	142,625,277	0	638,533,794	Carried
40.34%	10.89%			
1,173,802,179	202,470	0	135,333,217	Carried
89.65%	0.02%			
1,173,802,179	202,470	0	135,333,217	Carried
89.65%	0.02%			
1,149,238,712	180,687	0	159,918,467	Carried
87.77%	0.01%			
1,174,860,247	180,687	0	134,296,932	Carried
89.73%	0.01%			
1,176,478,369	232,970	0	132,626,527	Carried
89.85%	0.02%			
1,160,567,388	148,604,544	0	165,934	Carried
88.64%	11.35%			







^{*}votes cast by a person who abstains 0n an item are not counted in calculating the required majority on a poll.

For further information, please contact:

Bioxyne Limited

Sam Watson Chief Executive Officer info@bioxyne.com **NWR Communications**

Melissa Tempra Media & Investor Relations melissa@nwrcommunications.com.au

About Bioxyne Limited

Bioxyne Limited is a licensed Australian pharmaceutical and healthcare company manufacturing and distributing novel medicines, health products and active pharmaceutical ingredients including medicinal cannabis, MDMA, and Psilocybin.

About Breathe Life Sciences

Breathe Life Sciences ("BLS") is a wholly owned subsidiary of Bioxyne Ltd (BXN:ASX) and GMP-licensed manufacturer, wholesaler, importer and exporter of controlled substances (S3, S4, S8, S9), including medicinal cannabis, Psilocybin, and MDMA.

BLS was founded in 2018 and has quickly expanded into a multi-national business focused on alternative therapeutics and investigational medicines. The company's corporate head office is in Sydney, with operations and licensed manufacturing, warehousing, import/export, sales and distribution centres in Queensland (Australia), Nagoya (Japan), Manchester (UK), and Prague (Czechia).

The BLS business model is focused on manufacturing final dose form medicines, sales and distribution. BLS sources raw materials and API from suppliers in 5 continents and is the Australian market leading manufacturer of therapeutic goods including cannabis, MDMA, and Psilocybin.

Outside of Australia the BLS Group operates in pharmaceuticals, medical cannabis, consumer health products, and novel foods (CBD). In the UK, Europe and Japan, the Company engages in the following activities:

- a) Owner of Dr Watson® brand in the UK, Japan, Australia and New Zealand. Internationally recognized for its cannabis-based food supplements, health products, and prescription-only cannabis medicines.
- b) Contract drug manufacturing and white label manufacturing of scheduled medicines, therapeutic goods, medical devices, consumer health products, and active pharmaceutical ingredients. BLS manufactures over 200 of Australia's medicinal cannabis brands.
- c) Import, export, and wholesale of active pharmaceutical ingredients, starting materials, patient-ready medicinal products, and/ or consumer health products in Australia, Japan, UK, USA and Europe.
- d) Research and development of novel medicines.
- e) Direct sales via online and wholesale of BLS-owned consumer brands, such as Dr Watson®

United Kingdom: drwatsoncbd.com

UK / EU: breathelifesciences.com

Corporate: bioxyne.com

Australia: bls.com.au

International: breathelifesciences.com

